Abstract
Cardiovascular diseases are possible complications of antineoplastic treatment and may lead to premature morbidity and mortality amongcancer survivors. A symptom‑based follow‑up is ineffective, and there are growing evidences that early detection of myocardial damage inpatients treated with antineoplastic drugs is the key point to prevent the occurrence of damage and improve the prognosis of these patients.Different techniques have been proposed to monitor cardiac function in oncologic patients such as cardiac imaging (echocardiography, nuclearimaging, and cardiac magnetic resonance) and biomarkers (troponin and natriuretic peptides). The European Association of CardiovascularImaging/American Society of Echocardiography consensus document encourages an integrated approach to early detect
Lingua originale | English |
---|---|
Numero di pagine | 7 |
Rivista | JOURNAL OF CARDIOVASCULAR ECHOGRAPHY |
Stato di pubblicazione | Published - 2020 |
All Science Journal Classification (ASJC) codes
- Radiology Nuclear Medicine and imaging
- Cardiology and Cardiovascular Medicine